Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Monday morning,Benzinga reports. They currently have a $8.00 price objective on the stock.

GANX has been the topic of a number of other reports. Oppenheimer restated an “outperform” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, August 9th.

Gain Therapeutics Trading Up 5.8 %

GANX stock opened at $1.82 on Monday. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The stock has a market capitalization of $48.27 million, a price-to-earnings ratio of -1.65 and a beta of 0.33. The firm’s fifty day simple moving average is $2.07 and its two-hundred day simple moving average is $1.72.

Institutional Trading of Gain Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after acquiring an additional 72,000 shares during the period. Warberg Asset Management LLC purchased a new stake in Gain Therapeutics in the second quarter worth about $66,000. Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the second quarter worth about $422,000. Finally, Geode Capital Management LLC lifted its stake in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after acquiring an additional 88,236 shares during the period. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.